Dag R. Stormoen

Copenhagen, 2100, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

An example of drug repurposing: ebastine in combination with docetaxel as a treatment for metastatic castration-resistant prostate cancer-the EXUROC prostate study, a clinical trial protocol.

An example of drug repurposing: ebastine in combination with docetaxel as a treatment for metastatic castration-resistant prostate cancer-the EXUROC prostate study, a clinical trial protocol.

Journal: BMC urology

Published: May 28, 2025

Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer.

Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer.

Journal: The Journal of clinical investigation

Published: September 06, 2024

Assessing expression patterns of PTGR1, a potential biomarker for acylfulven sensitivity in urothelial carcinoma.

Assessing expression patterns of PTGR1, a potential biomarker for acylfulven sensitivity in urothelial carcinoma.

Journal: Scientific reports

Published: August 05, 2024

Similar genetic profile in early and late stage urothelial tract cancer.

Similar genetic profile in early and late stage urothelial tract cancer.

Journal: Journal of cancer research and clinical oncology

Published: May 13, 2024

Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer.

Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer.

Journal: European urology

Published: January 03, 2024

ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.

ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.

Journal: Science advances

Published: November 22, 2023

Glomerular filtration rate measurement during platinum treatment for urothelial carcinoma: optimal methods for clinical practice.

Glomerular filtration rate measurement during platinum treatment for urothelial carcinoma: optimal methods for clinical practice.

Journal: International journal of clinical oncology

Published: October 25, 2023

Patient-reported outcomes used actively in cancer patients undergoing antineoplastic treatment: A mini-review of the Danish landscape.

Patient-reported outcomes used actively in cancer patients undergoing antineoplastic treatment: A mini-review of the Danish landscape.

Journal: Computational and structural biotechnology journal

Published: September 22, 2023

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma.

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma.

Journal: Scientific reports

Published: August 08, 2023

Association of patient-reported pain with survival in bladder cancer: a post-hoc analysis of the iBLAD trial.

Association of patient-reported pain with survival in bladder cancer: a post-hoc analysis of the iBLAD trial.

Journal: Acta oncologica (Stockholm, Sweden)

Published: April 18, 2023

Title Not Found

Title Not Found

Journal: Ugeskrift for laeger

Published: April 14, 2023

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma.

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma.

Journal: bioRxiv : the preprint server for biology

Published: February 17, 2023

Showing 1-12 of 19

Last Updated: 09/26/2026